Literature DB >> 26223499

Mutational profile of childhood myeloproliferative neoplasms.

A Karow1, R Nienhold1, P Lundberg1, E Peroni2, M C Putti3, M L Randi2, R C Skoda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26223499     DOI： 10.1038/leu.2015.205

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

1.  Incidence of essential thrombocythaemia in children.

Authors:  H Hasle
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

Review 2.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

3.  CALR mutations are rare in childhood essential thrombocythemia.

Authors:  Stephen E Langabeer; Karl Haslam; Corrina McMahon
Journal:  Pediatr Blood Cancer       Date:  2014-02-13       Impact factor: 3.167

4.  CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence.

Authors:  Fiorina Giona; Luciana Teofili; Sara Capodimonti; Marica Laurino; Maurizio Martini; Deborah Marzella; Giovanna Palumbo; Daniela Diverio; Robin Foà; Luigi Maria Larocca
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

7.  Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Authors:  Luciana Teofili; Fiorina Giona; Maurizio Martini; Tonia Cenci; Francesco Guidi; Lorenza Torti; Giovanna Palumbo; Angela Amendola; Robin Foà; Luigi M Larocca
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

8.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

9.  Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia.

Authors:  Iwona Konieczna; Elizabeth Horvath; Hao Wang; Stephan Lindsey; Gurveen Saberwal; Ling Bei; Weiqi Huang; Leonidas Platanias; Elizabeth A Eklund
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
View more
  8 in total

1.  Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.

Authors:  Nicole Kucine; Aaron D Viny; Raajit Rampal; Michael Berger; Nicholas Socci; Agnes Viale; James B Bussel; Ross L Levine; Franck Rapaport
Journal:  Haematologica       Date:  2016-03-18       Impact factor: 9.941

2.  Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.

Authors:  Nya D Nelson; Andrea Marcogliese; Katie Bergstrom; Michael Scheurer; Donald Mahoney; Alison A Bertuch
Journal:  Pediatr Blood Cancer       Date:  2016-04-21       Impact factor: 3.167

Review 3.  Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

Authors:  Jeffrey Patterson-Fortin; Alison R Moliterno
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

4.  Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.

Authors:  Hyoung Soo Choi; Junshik Hong; Sang Mee Hwang; Ju Hyun Lee; Youngeun Ma; Sang-A Kim; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang
Journal:  Ann Hematol       Date:  2021-07-30       Impact factor: 3.673

5.  Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Authors:  Jean-Christophe Ianotto; Natalia Curto-Garcia; Marie Lauermanova; Deepti Radia; Jean-Jacques Kiladjian; Claire N Harrison
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 6.  Essential Thrombocythemia in Children and Adolescents.

Authors:  Maria Caterina Putti; Irene Bertozzi; Maria Luigia Randi
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

7.  IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.

Authors:  Xiao Huang; Tingting Ma; Yongmei Zhu; Bo Jiao; Shanhe Yu; Kankan Wang; Jian-Qing Mi; Ruibao Ren
Journal:  Front Med       Date:  2021-07-31       Impact factor: 9.927

8.  Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?

Authors:  Tariq I Mughal; Michael W Deininger; Nicole Kucine; Giuseppe Saglio; Richard A Van Etten
Journal:  Hemasphere       Date:  2019-08-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.